ClinicalTrialsFinder
RecruitingPhase 1NCT07093580

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

Phase 1 Study of a Long-acting Injectable S-892216 in Healthy Adult Participants

Sponsor

Shionogi

Enrollment

98 participants

Start Date

Jul 29, 2025

Study Type

INTERVENTIONAL

Conditions

Healthy Participants

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called S-892216-LAI for people with healthy participants. The study is currently recruiting participants at 2 locations. People eligible for this study include men aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGS-892216-LAI

S-892216-LAI injection will be administered per schedule specified in the arm description.

DRUGPlacebo

Physiological saline will be administered per schedule specified in the arm description.

Locations(2)

ICON Clinical Research: Lenexa

Lenexa, Kansas, United States

ICON Clinical Research: Salt Lake City

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07093580

Related Trials

A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants

NCT076418811 location

A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

NCT076224331 location

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT075390901 location

Cognition and Ultrasound

NCT072206551 location

Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants

NCT071106101 location